Clinical Trials

Clinical trials are systematic investigations in human subjects designed to evaluate the safety and efficacy of a medical, surgical, or behavioral intervention. They are governed by international ethical and scientific quality standards, primarily the International Council for Harmonisation's Good Clinical Practice (ICH E6(R2)). In the U.S., they are regulated by the FDA under Title 21 of the Code of Federal Regulations (CFR). Within enterprise risk management, trials represent a critical operational risk involving patient safety, data integrity, regulatory compliance, and immense financial investment. They are structured in phases (I, II, III, IV) as a core risk mitigation strategy, ensuring safety is established before exposing large populations. This process is distinct from preclinical research, which involves non-human subjects and precedes human testing.

In enterprise risk management, clinical trials are managed through a structured approach. Step 1: Risk-Based Protocol Design, which involves using tools like FMEA during the planning phase to identify risks to patient safety, data quality, or timelines. Step 2: Implementation of GCP-Compliant Controls, establishing a robust Quality Management System (QMS) with SOPs and using validated systems like Electronic Data Capture (EDC) compliant with 21 CFR Part 11 to ensure data integrity. Step 3: Continuous Monitoring and Auditing, which applies risk-based monitoring (RBM) to focus resources on high-risk sites and processes, supplemented by independent audits. For example, a global pharma company reduced data query rates by 30% and accelerated database lock by 20% by implementing a centralized RBM strategy, improving its audit pass rate.

Taiwan enterprises face three key challenges in global clinical trials. First, Navigating Multi-Regional Regulations, managing divergent submission and safety reporting requirements for Taiwan's TFDA, US FDA, and EMA. The solution is a unified QMS based on ICH guidelines, supported by Regulatory Information Management (RIM) software. Second, Limited Patient Pools, where Taiwan's smaller population makes recruitment for certain diseases difficult. Mitigation involves participating in Multi-Regional Clinical Trials (MRCTs) and adopting patient-centric, decentralized trial models. Third, Data Privacy and Security, ensuring compliance with laws like GDPR for international data transfer. The strategy is to implement an ISO/IEC 27001 certified ISMS and conduct Data Protection Impact Assessments (DPIAs). Priority should be given to establishing the compliant QMS framework.

Winners Consulting specializes in Clinical trials for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact